New Alzheimer's Treatments to See Research Debut Soon

Researchers will present data on two tau-targeting therapies for Alzheimer's disease in Boston this November.

Updated on Oct. 27, 2026 in Alzheimer’s

A glass vial containing a refined crystalline molecular structure rests on a white clinical surface in a bright laboratory. — Voyager Therapeutics plans to present early-stage clinical research on two tau-targeting Alzheimer's treatments at the upcoming CTAD conference in Boston. AI Illustration. Upload story photo >

Live Poll

Will new clinical research provide more effective treatments for Alzheimer's patients in the near future?

Voyager Therapeutics will present new research on two investigational Alzheimer's treatments, VY1706 and VY7523, at the 19th Clinical Trials on Alzheimer's Disease Conference in Boston. The presentations are scheduled to take place between November 16 and November 17, 2026.

Why it matters

These presentations offer a look at early-stage approaches targeting tau protein, a key factor in Alzheimer's disease pathology. The data provides insights into developing gene and antibody therapies that aim to modify the progression of the condition.

The upcoming findings involve preliminary research on two novel approaches, with data presented as posters for VY1706 and VY7523. The clinical impact of these therapies versus established Alzheimer's treatments is currently unknown as the study results are still being disclosed.

The players

Voyager Therapeutics

A biotechnology company based in Lexington, Massachusetts, focused on developing gene therapies for neurological diseases.

Elena Ratti

The researcher and presenter who will share the new findings on behalf of the company.

The details

VY1706 is a gene therapy designed to lower the production of tau proteins, which are known to aggregate in the brains of individuals with Alzheimer's disease. VY7523 is a monoclonal antibody that targets the C-terminal region of tau to address these accumulations. By tackling tau-related pathology, these treatments aim to intervene in the biological mechanisms that contribute to the neurodegeneration seen in the disease.

• November 16, 2026, at 2:00 p.m.: Poster presentations begin at the conference.
• November 17, 2026, at 5:30 p.m. ET: Poster presentations conclude.
• November 16-19, 2026: The 19th Clinical Trials on Alzheimer's Disease Conference takes place in Boston.

Health Landscape

This development reflects the current shift in Alzheimer's research toward targeting tau protein aggregation alongside traditional amyloid-beta targets. It adds to the expanding landscape of gene and monoclonal antibody therapies currently being evaluated in preclinical and clinical settings.

These findings are early-stage and represent research developments rather than available clinical treatments. If you are managing Alzheimer's, it is worth discussing with your neurologist or primary care physician how emerging tau-targeting therapies may fit into the evolving landscape of care.

The takeaway

Targeting tau proteins remains a major focus for researchers seeking to alter the course of Alzheimer's disease. Keep informed on emerging study results by following updates from reputable clinical trial registries or discussing new research directions during your next specialist appointment.